Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
3.840
+0.100 (2.67%)
At close: Aug 17, 2026, 4:00 PM EDT
3.820
-0.020 (-0.52%)
After-hours: Aug 17, 2026, 7:43 PM EDT
Fulcrum Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
292.98M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 80.00M | 77.20M | 2,752.05% |
| Dec 31, 2023 | 2.81M | -3.54M | -55.77% |
| Dec 31, 2022 | 6.34M | -12.82M | -66.90% |
| Dec 31, 2021 | 19.16M | 10.34M | 117.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bicycle Therapeutics | 61.21M |
| Sol-Gel Technologies | 18.47M |
| Surrozen | 11.51M |
| Opus Genetics | 9.86M |
| Fate Therapeutics | 6.49M |
FULC News
- 9 hours ago - Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) for Potential Violations of the Federal Securities Laws - Newsfile Corp
- 12 hours ago - Fulcrum to merge with Slate in all-stock deal after drug setback - Reuters
- 12 hours ago - Fulcrum Therapeutics Transcript: M&A announcement - Transcripts
- 12 hours ago - Fulcrum Therapeutics Press release: M&A announcement - Filings
- 13 hours ago - Fulcrum Therapeutics, Slate Medicines to combine in an all-stock transaction - TheFly
- 13 hours ago - Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies - GlobeNewsWire
- 18 days ago - Fulcrum Therapeutics Quarterly report: Q2 2026 - Filings
- 19 days ago - Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (FULC) Investors of a Securities Investigation into the Company - Newsfile Corp